Despite modern advances in antibiotic therapy and cardiovascular support, septic shock remains a condition plagued by a high mortality rate, estimated at 40-60%. The pathogenesis of septic shock involves a complex orchestration of cytokines which lead to vasodilation, increased capillary permeability, and disturbances of metabolism. The major clini-cal features include hypotension, tissue hypoperfusion, myocardial depression, and organ failures. Cur-rent therapy focuses on early broad-spectrum antibiotic treatment, correction of hypovolemia, and appropriate use of vasopressor and/or inotropic agents. Experimental attempts to intervene in the septic cytokine cascade hold promise, but none have shown a definitive clinical benefit. This review examines the pathogenesis, clinical features, current therapeutic approaches, and future prospects for this serious prob-lem.